Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417773 | 0.88 | MAPT (0.45) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL237380 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 0.84 | — | — | |
| SCHEMBL8891623 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2375356 | 0.84 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL8113396 | 0.84 | PPM1B (0.47) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL3552997 | 0.83 | MAPT (0.53) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3959176 | 0.82 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28788727 | 0.82 | — | — | |
| SCHEMBL6622331 | 0.81 | ALDH1A1 (0.44) | ALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| EP-2379496-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-04 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | claimed |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | claimed |
| EP-1566378-B1 | ISOINDOLINE DERIVATIVE | MARUISHI PHARMA (JP) | 2012-08-15 | — | — | EP | claimed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| US-8148422-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-03 | — | — | US | claimed |
| US-5869486-A | EXHIBIT INHIBITORY ACTIVITY ON CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE; ADMINISTERING TO TREAT CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-02-09 | — | — | US | claimed |
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| US-5741790-A | Azetidines | PFIZER INC. (US) | 1998-04-21 | — | — | US | claimed |
| EP-0791592-A2 | Azetidines | Pfizer Limited (GB) | 1997-08-27 | — | — | EP | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | claimed |
| EP-0728759-A1 | Heterocyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-28 | — | — | EP | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | claimed |
| EP-0005232-B1 | ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-08-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MAPT 708/4885ALDH1A1 2155/4885PPM1B 2771/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | MAPT 2813/4885ALDH1A1 2797/4885PPM1B 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.